

Product Name: BNP (1-32), human Revision Date: 01/10/2021

Product Data Sheet

BNP (1-32), human

Cat. No.: A1105

114471-18-0 CAS No.:

Formula: C143H244N50O42S4

M.Wt: 3464.04

H2N-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cy Synonyms:

s-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-S


er-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-

His-OH

Cardiovascular Target:

Pathway:

Store at -20°C Storage:



Solvent & Solubility

 \geqslant 206.6 mg/mL in DMSO

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	0.2887 mL	1.4434 mL	2.8868 mL
	5 mM	0.0577 mL	0.2887 mL	0.5774 mL
	10 mM	0.0289 mL	0.1443 mL	0.2887 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

_ Biologica	I Activity	APENBIO
Shortsummary	Brain natriuretic peptide	
IC ₅₀ & Target		
In Vitro	Cell Viability Assay	
	Cell Line:	Normal adult canine ventricular fibroblasts
	Preparation method:	The solubility of this peptide in sterile water is >10 mM. Stock solution should
		be splited and stored at -80°C for several months.

	Reacting conditions:	1 μM, 5 min			
	Applications:	BNP (1 µM) significantly increased the intracellular cGMP, whereas lower			
		concentrations did not alter the cGMP. At this concentration, BNP elevated			
		cGMP levels with a maximal effect at 5 minutes. BNP (1 µM) significantly			
		inhibited the [3H]proline incorporation into the cells by 29%.			
	Animal experiment	Animal experiment			
In Vivo	Animal models:	Adult Japanese white rabbits			
	Dosage form:	Injected through the sclera into the vitreous cavity, 100 μM, 4 hours			
	Applications:	At 100 μM, BNP treatment induced a significant decrease in IOP compared			
		with vehicle-treated eyes. In particular, there were statistically significant			
		differences at 4 and 6 hours. In addition, BNP treatment at 10 μM caused a			
		significant decrease in IOP compared to the vehicle-treated eyes, but only at 6			
		hours after the injection.			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may			
	810	slightly differ with the theoretical value. This is caused by an experimental			
	DE LOS CONTRACTOR DE LA	system error and it is normal.			

Product Citations

See more customer validations on www.apexbt.com.

References

- [1] Tsuruda T, Boerrigter G, Huntley B K, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circulation research, 2002, 91(12): 1127-1134.
- [2] Takashima Y, Taniguchi T, Yoshida M, et al. Ocular hypotensive mechanism of intravitreally injected brain natriuretic peptide in rabbit. Investigative ophthalmology & visual science, 1996, 37(13): 2671-2677.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE BIO

APE BIO

APE BIO

APE BIO

APE BIO

APEVEIO.